Pharmaco-Immunomodulatory Therapy in COVID-19

Area of Science:

• Immunology
• Pharmacology
• Virology

Background:

• COVID-19 pathogenesis involves viral replication and a detrimental host inflammatory response.
• The cytokine storm and immune evasion are critical factors in COVID-19 severity and outcomes.
• Elevated proinflammatory cytokines correlate with increased mortality in advanced COVID-19 stages.

Purpose of the Study:

• To review the potential role and safety of immune modulators in managing severe COVID-19.
• To discuss the impact of these agents on patient survival and clinical symptoms.
• To highlight the importance of optimal timing for immunomodulatory interventions.

Main Methods:

• Literature search conducted on PubMed, Google Scholar, and ClinicalTrials.gov up to July 8, 2020.
• Keywords included 'coronavirus', 'immunology', 'cytokine storm', 'immunomodulators', 'pharmacology', 'SARS-CoV-2', and 'COVID-19'.
• Review of specific and non-specific immune modulators, including receptor antagonists, JAK inhibitors, corticosteroids, and others.

Main Results:

• Specific immune modulators evaluated include IL-1/IL-6 receptor antagonists, JAK inhibitors, anti-TNF-α agents, and convalescent plasma.
• Non-specific modulators include corticosteroids (dexamethasone), interferons, statins, and macrolides.
• Dexamethasone (6 mg daily for 10 days) demonstrated a significant reduction in mortality for ventilated and oxygen-dependent COVID-19 patients.

Conclusions:

• Immune modulators offer potential therapeutic benefits for severe COVID-19 by inhibiting the cytokine storm.
• Dexamethasone shows a clear survival benefit, particularly in critically ill patients.
• Further research should focus on identifying the most effective immunomodulatory strategies and their optimal administration timing.